CN101167735A - 一种用于提高精子质量、治疗男性不育症的药物 - Google Patents
一种用于提高精子质量、治疗男性不育症的药物 Download PDFInfo
- Publication number
- CN101167735A CN101167735A CNA2006101426609A CN200610142660A CN101167735A CN 101167735 A CN101167735 A CN 101167735A CN A2006101426609 A CNA2006101426609 A CN A2006101426609A CN 200610142660 A CN200610142660 A CN 200610142660A CN 101167735 A CN101167735 A CN 101167735A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- sperm
- medicine
- improve
- quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title description 7
- 230000036512 infertility Effects 0.000 title description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 208000007466 Male Infertility Diseases 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 15
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 13
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims abstract description 13
- 229960003608 clomifene Drugs 0.000 claims abstract description 13
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 13
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 13
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 13
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000342 retinol acetate Drugs 0.000 claims abstract description 12
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims abstract description 12
- 235000019173 retinyl acetate Nutrition 0.000 claims abstract description 12
- 239000011770 retinyl acetate Substances 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- CWCBDTQKPQWMBA-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;selenium Chemical compound [Se].OC(=O)CC(O)(C(O)=O)CC(O)=O CWCBDTQKPQWMBA-UHFFFAOYSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960003121 arginine Drugs 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000287680 Garcinia dulcis Species 0.000 abstract 1
- PFNRUAXUGKZZGL-UHFFFAOYSA-N OC(CC(O)=O)(CC(O)=O)C(O)=O.[SeH2] Chemical compound OC(CC(O)=O)(CC(O)=O)C(O)=O.[SeH2] PFNRUAXUGKZZGL-UHFFFAOYSA-N 0.000 abstract 1
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 229910052711 selenium Inorganic materials 0.000 description 6
- 230000021595 spermatogenesis Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000469 anti-sperm effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010021929 Infertility male Diseases 0.000 description 2
- 206010039954 Seminal vesiculitis Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 235000013410 fast food Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010014328 Ejaculation failure Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010038967 Retrograde ejaculation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- WIKSRXFQIZQFEH-UHFFFAOYSA-N [Cu].[Pb] Chemical compound [Cu].[Pb] WIKSRXFQIZQFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000001535 kindling effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000004908 prostatic fluid Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种用于提高精子质量、治疗男性不育症的药物。该药物是由如下的成分构成：左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯，且左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1。制备上述用于提高精子质量、治疗男性不育症的药物的方法，是由如下步骤构成：(1)将药物的各成分按比例选取合格原料混合均匀；(2)加入赋形辅料再一次混合均匀；(3)干燥后制成口服制剂。本发明的药物对于提高精子质量、治疗男性不育症疗效显著、服用方便，各组分协同作用减少了毒副作用而增加了疗效。
Description
1、技术领域：
本发明涉及一种用于提高精子质量、治疗男性不育症的药物，尤其涉及一种由左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯组成的用于提高精子质量、治疗男性不育症的药物。
2、背景技术：
有统计表明，近50年来，男性的精液质量不断下降，导致暂时或永久性的不育，或者胎儿质量下降，给家庭带来极大的痛苦，成为必须重视的社会问题。
1998年国家计科所曾在对1981-1996年16年间公开发表的，来源于北京、上海、天津等39个市县、256份文献共11726人的数据进行分析后发现，精液质量正以每年1％的速度下降，而且下降速度越来越快。
2002年成都计划生育技术指导所李刚等人在完成对成都地区12所高校295名在校大学生调查后，在《现代预防医学》杂志上发表《成都地区大学生精子质量及抗精子抗体的调查》的论文，揭示精子质量异常者99人占33.56％；扩大范围至14所高校549名在校大学生调查后，在2003年12月的《中华男科学》上发表了《成都地区549例大学生精子质量调查》的论文，揭示精子质量异常者204人占37.16％，并惊呼“将来不育症的发生率可能高于目前文献报道的12％--16％，甚至可超1/3”。
精子质量下降而至男性不育症原因主要有如下几种：
1、性乱导致性病，损伤了男性的生殖功能，使精子存活率降低；
2、环境污染，汽车、摩托车排放的有毒废气，使男性性功能衰退，精子畸变；厨房中的油烟也能使细胞发生突变，导致不育；育龄男性吃了有农药残留的蔬菜、水果，会减少精子生成过程中的能量供应，导致畸形儿的形成；
3、抽烟喝酒，经常抽烟的男性不育的概率为不吸烟男性的3倍，不完整的精子数也比正常男性高出许多；酒精则可使精子头尾畸形、活力降低，也容易导致胎儿畸形。
4、与电器接触过频，长时间与家用电器、计算机、手机、广播等电子产品接触，可使人遭受电磁波及射线之害，造成男性无精子生成或生成异常精子而导致不育或胎儿畸形。
5、内衣过紧或穿紧身皮裤，这不但压迫男性生殖器官，影响睾丸正常发育，还因不透气、不散热而影响精子生存。
6、泡热水澡，适合精子发育的温度为34℃左右，高温对精子发育产生不良影响，因此，应慎重对待高温作业及热水澡、桑拿、夏天不开空调而长时间开车等。
7、偏食挑食，精子的生成和发育离不开营养，故偏食挑食将导致精子营养不良而影响生育。
8、长期服药，降压药、利尿药、抗菌药以及治疗心脏病、胃溃疡的药物都有损伤精子的弊端。
9、吸毒，男性吸毒可使血液中的睾丸酮水平下降，生殖能力削弱，不能射精，从而导致不育。
10、久骑赛车，骑赛车时由于重心前倾，会阴部的睾丸、前列腺紧贴在坐垫上，受到长时间挤压后会缺血、水肿、发炎，影响精子的生成及前列腺液和精液的正常分泌而导致不育。
11、洗洁精、杀虫剂，杀灭细菌的同时也损伤男性的生殖系统并导致男性激素分泌失衡。
12、快餐，快餐食物中含有一种类似雌性激素的荷尔蒙，如果这种荷尔蒙的摄取量较大的话，会显现一些人类雌性激素的效果，从而诱发男性生殖问题。
13、连续驾车，连续驾车超过2个小时足以损害男性精子质量。
14、药物，许多药物对精子的生成及男性的性功能等有不良的影响。
15、性功能障碍，如阳痿、早泄、不射精、逆行射精等也将影响男性生育。
16、性欲过度，导致生精物质缺乏，精子质量下降，影响男性生育。
17、精神紧张、生物节律紊乱，导致内分泌失调，精子质量下降，影响男性生育。
为了治疗男性不育，目前主要采用如下几种治疗方法：
(1)体外受精-胚胎移植；
(2)卵胞浆内单精子显微注射；
(3)供精人工授精技术；
(4)营养类药物；
(5)激素类药物；
(6)中药和中药保健品。
上述方法都有其不足之处，其中，(1)、(2)、(3)三项方法一个疗程的有效率为20-40％，费用约1.5~3万元，且须去全国有资质的仅仅数十家医院住院治疗，但不仅不能提高精子质量而且会因超低温冷冻而损伤精子；(4)、(5)两项方法，单组分剂量大、毒副作用明显而效果不明显；第(6)项方法服用不方便，疗效的逻辑关系不紧密，且费用较高(2~10万元)。
3、发明内容：
本发明的目的在于提供一种用于提高精子质量、治疗男性不育症的药物，该药物疗效显著、服用方便、且无毒副作用。
为实现上述目的，本发明的药物是由如下的成分构成：左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯。
本发明所述的左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1，具体比例可以是从140∶140∶7∶7∶7∶3.5∶1∶1至100∶100∶5∶5∶5∶2.5∶1∶1，也可以是从80∶80∶4∶4∶4∶2∶1∶1至100∶100∶5∶5∶5∶2.5∶1∶1。
制备上述用于提高精子质量、治疗男性不育症的药物的方法，是由如下步骤构成：(1)按左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1选取合格原料混合均匀；(2)加入赋形辅料再一次混合均匀；(3)干燥后制成口服制剂。
所述的口服制剂可为片剂、颗粒剂、胶囊剂、软胶囊剂。
本发明与目前主要采用的6种治疗方法相比，其有益效果在于：该药物的各组分是发明人经过长期探索而筛选出的药理互补协同，作用明显、且无毒副作用的组合，在实际使用过程中，能提高阴茎勃起力度，能提高精子质量，稳定精子的遗传信息，治疗男性因精子质量和数量原因而导致的不育症，提高胎儿质量，疗效显著(对精子的改善率约为80％)；且可大幅降低治疗费用又不须住院，不影响日常工作和生活，能广泛使用。
本发明的药物仅约0.5％的使用者会出现作呕等肠胃反应，与目前用于治疗男性不育症的6类方法相比，低不良反应方面的优势突出。
发明能为下列人群提供疗效：
1、因精子质量原因患不育症但又想生育的男人，占育龄男性的12％；
2、性欲不振又想生育的男人，占育龄男性的20％；
3、因精子质量原因患不育症但又想用自己的精子去医院人工授精的求真男人，占育龄男性的5％；
4、想优生优育一个质量更高的子女的好男人，占育龄男性的100％。
具体实施方式：
以下所述仅为体现本发明原理的较佳实施例，并不因此而限定本发明的保护范围。
本发明的药物是由如下重量比的成分构成：左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1。
其中各组分的作用是：
左旋肉碱的作用在于：(1)参与精子能量代谢，提高精子活力；(2)参与生成精子细胞膜，提高精子完好率和寿命；(3)增加精子数量。
精氨酸的作用在于：(1)参与精子生成，提高精子质量和数量；(2)增加精子细胞新陈代谢所需的能量，提高精子的活力，延长其生存时间；(3)调节睾丸酮等生殖激素，提高性功能以及产精的速度和数量；(4)提高精子对ATP的生成与利用，提高精子活力；(5)、生成NO，促进阴茎勃起。
维生素E醋酸酯的作用在于：(1)维生素E醋酸酯缺乏可使睾丸曲细精管变性，导致生精障碍；(2)抑制造成男性附属性腺炎症的前列腺素的氧化产物，因而可避免精子活力低下问题；(3)抗氧化，稳定精子膜，提高精子质量和存活率。
核苷酸的作用在于：(1)增加精了细胞代谢所需的能量，提高精了活力；(2)作为精子中的遗传物质，如核糖核酸及脱氧核糖核酸的原材料，稳定精子的遗传信息。
葡萄糖酸锌的作用在于：(1)干扰铜铅等有毒物质的吸收，从而减轻对精子的毒害；(2)参与精子生成，提高精子质量和数量；(3)提高精子的活力，抗氧化，稳定精子膜，提高精子质量和存活率；(4)免疫调节功能，对精浆抗精子抗体阳性、血清抗精子抗体阳性不育有效；(5)减轻炎症，对精囊炎及精囊炎导致的不育有效。
克罗米芬的作用在于：(1)使下丘脑分泌促性腺激素释放激素增加及垂体分泌促性腺激素增加，从而提高睾丸的生精能力，利于精子的产生，增加精子数；(2)调节睾丸酮等生殖激素，提高性功能以及产精的速度和数量。
柠檬酸硒的作用在于：(1)硒是人类生长、发育过程中的必需微量元素之一，硒主要集中在睾丸和前列腺输精管中，并生成两种精子特异硒蛋白，硒被国内外医药界和营养学界尊称为“生命火种”；(2)消除体内有害物质，保护组织免受有毒物质侵害，对机体内有害金属元素起抵抗作用；(3)提高精子活力。(4)硒可和精液一起排出体外而导致缺硒性不育症，须补充。
维生素A的作用在于：促进精子生成，提高精子活力。
本发明的药物制备应在符合GMP要求的口服制剂生产线上进行，其步骤如下：(1)按左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1选取合格原料混合均匀；(2)加入赋形辅料再一次混合均匀；(3)干燥后制成口服制剂。口服制剂为根据设备及市场需要而制成片剂、颗粒剂、胶囊剂、软胶囊剂。
本发明的药物的服用方法如下：每日睡前温开水送服，每次一剂，每个疗程为3个月。
Claims (5)
1.所述的一种用于提高精子质量、治疗男性不育症的药物，其特征在于，它是主要由：左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯组成，左旋肉碱、精氨酸、葡萄糖酸锌、维生素E、核苷酸、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1。
2.根据权利要求1一种用于提高精子质量、治疗男性不育症的药物，其特征在于左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是由从140∶140∶7∶7∶7∶3.5∶1∶1至100∶100∶5∶5∶5∶2.5∶1∶1。
3.根据权利要求1一种用于提高精子质量、治疗男性不育症的药物，其特征在于左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是由从80∶80∶4∶4∶4∶2∶1∶1至100∶100∶5∶5∶5∶2.5∶1∶1。
4.制备权利要求1所述的用于提高精子质量、治疗男性不育症的药物的方法，其特征在于，它由如下步骤构成：(1)按左旋肉碱、精氨酸、维生素E、核苷酸、葡萄糖酸锌、克罗米芬、柠檬酸硒、维生素A醋酸酯的比例是从140∶140∶7∶7∶7∶3.5∶1∶1至80∶80∶4∶4∶4∶2∶1∶1选取合格原料混合均匀；(2)加入赋形辅料再一次混合均匀；(3)干燥后制成口服制剂。
5.根据权利要求4所述的制备用于提高精子质量、治疗男性不育症的的药物的方法，其特征在于：所述的口服制剂可为片剂、颗粒剂、胶囊剂、软胶囊剂。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101426609A CN101167735A (zh) | 2006-10-27 | 2006-10-27 | 一种用于提高精子质量、治疗男性不育症的药物 |
| PCT/CN2007/003048 WO2008052432A1 (fr) | 2006-10-27 | 2007-10-26 | Médicament pour améliorer la qualité du sperme et traiter la stérilité chez l'homme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101426609A CN101167735A (zh) | 2006-10-27 | 2006-10-27 | 一种用于提高精子质量、治疗男性不育症的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101167735A true CN101167735A (zh) | 2008-04-30 |
Family
ID=39343811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101426609A Withdrawn CN101167735A (zh) | 2006-10-27 | 2006-10-27 | 一种用于提高精子质量、治疗男性不育症的药物 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101167735A (zh) |
| WO (1) | WO2008052432A1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953844A (zh) * | 2010-02-28 | 2011-01-26 | 黄胜先 | 一种用于提高精子质量、治疗男性不育症的药物 |
| CN104083468A (zh) * | 2014-05-31 | 2014-10-08 | 山东欣希安药业股份有限公司 | 一种治疗男性少精弱精、提高精子质量的药物 |
| CN106074598A (zh) * | 2016-06-14 | 2016-11-09 | 奥格生物技术（六安）有限公司 | 一种治疗精液异常男性不育症的复方有机螯合微量元素组合物及其制备方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1395255B1 (it) * | 2009-07-09 | 2012-09-05 | Mastelli S R L | Composizione per il trattamento di infertilita' maschile |
| CN112544987A (zh) * | 2020-12-03 | 2021-03-26 | 山东腾贵医药有限公司 | 一种提高精子活性的组合物及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5793913A (en) * | 1980-12-03 | 1982-06-11 | Ajinomoto Co Inc | Enhancing agent for spermous vital power |
| WO2003086080A1 (en) * | 2002-04-08 | 2003-10-23 | The Daily Wellnes Company | Method and composition for improving fertility health in female and male animals and humans |
-
2006
- 2006-10-27 CN CNA2006101426609A patent/CN101167735A/zh not_active Withdrawn
-
2007
- 2007-10-26 WO PCT/CN2007/003048 patent/WO2008052432A1/zh active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953844A (zh) * | 2010-02-28 | 2011-01-26 | 黄胜先 | 一种用于提高精子质量、治疗男性不育症的药物 |
| CN104083468A (zh) * | 2014-05-31 | 2014-10-08 | 山东欣希安药业股份有限公司 | 一种治疗男性少精弱精、提高精子质量的药物 |
| CN106074598A (zh) * | 2016-06-14 | 2016-11-09 | 奥格生物技术（六安）有限公司 | 一种治疗精液异常男性不育症的复方有机螯合微量元素组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008052432A1 (fr) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102669495A (zh) | 一种小麦型仔猪14-35日龄配合饲料及其制备方法 | |
| CN101167735A (zh) | 一种用于提高精子质量、治疗男性不育症的药物 | |
| CN103041007A (zh) | 一种治疗妇科炎症的外用复合药物 | |
| CN104208240A (zh) | 一种用于防治仔猪细菌性痢疾的中草药微生态制剂及其制备方法 | |
| CN106036878A (zh) | 一种男性生殖细胞修复专用营养制剂及其制备方法 | |
| CN102038679B (zh) | 一种双唑泰阴道凝胶及其制备方法 | |
| JP2009542800A (ja) | 金属の吸収を促進する金属−酸性アミノ酸キレートを含有する組成物 | |
| CN104256651B (zh) | 改善男性性功能的组合物及其制备方法和应用 | |
| KR100487887B1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는효모추출물, 이를 포함하는 조성물, 및 이들의 제조 방법 | |
| CN101129397A (zh) | 一种用于治疗男性不育症的药物及其制备方法 | |
| CN1437956A (zh) | 防治癌症的五毒鸡及其制备方法 | |
| JP2008044879A (ja) | ラクトフェリンを含有する医薬組成物ならびに加工食品 | |
| CN101953844A (zh) | 一种用于提高精子质量、治疗男性不育症的药物 | |
| Pojer | Integrative Treatment of Male Infertility with Chinese Medicine | |
| CN110384731A (zh) | 一种多功能药食同源组合物及其制备方法 | |
| CN104306405B (zh) | 提高肛肠免疫力预防便秘和肛肠疾病的保健栓剂及其制备方法和应用 | |
| JP2007506645A (ja) | 抗腫瘍および抗転移のための製剤の製造におけるｎ−アセチル−ｄ−グルコサミンの使用 | |
| Yakubu | Knocking Down the Barriers to Four O'Clock Activities and Reproductive Inadequacies | |
| JP2013079218A (ja) | 更年期障害改善用医薬組成物ならびに飲食物 | |
| CN103689298B (zh) | 用于治疗僵猪的饲料及其制备方法 | |
| KR20110131140A (ko) | 오미자 효소의 호르몬 치유와 프로테인 식이요법 | |
| CN101612392A (zh) | 一种用于预防和治疗哺乳动物子宫内膜炎的制剂及其制备方法 | |
| Komar | A qualitative study to determine the efficacy of the homoeopathic similimum in the treatment of premenstrual syndrome | |
| Wally | The Effect of Natural Honey Administration on Some Sperm Function Parameters in Male Infertility Patients | |
| Bathija | Female Reproductive System & Herbal Healing vs. Prescription Drugs and their Side Effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20080430 |